IL128280A0 - Method fro treating bipolar disorder - Google Patents

Method fro treating bipolar disorder

Info

Publication number
IL128280A0
IL128280A0 IL12828097A IL12828097A IL128280A0 IL 128280 A0 IL128280 A0 IL 128280A0 IL 12828097 A IL12828097 A IL 12828097A IL 12828097 A IL12828097 A IL 12828097A IL 128280 A0 IL128280 A0 IL 128280A0
Authority
IL
Israel
Prior art keywords
bipolar disorder
treating bipolar
method fro
fro treating
disorder
Prior art date
Application number
IL12828097A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL128280A0 publication Critical patent/IL128280A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Steroid Compounds (AREA)
  • Press Drives And Press Lines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrolytic Production Of Non-Metals, Compounds, Apparatuses Therefor (AREA)
  • Processing Of Solid Wastes (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL12828097A 1996-08-01 1997-07-28 Method fro treating bipolar disorder IL128280A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2290096P 1996-08-01 1996-08-01
PCT/US1997/013185 WO1998005324A1 (en) 1996-08-01 1997-07-28 Method for treating bipolar disorder

Publications (1)

Publication Number Publication Date
IL128280A0 true IL128280A0 (en) 1999-11-30

Family

ID=21812011

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12828097A IL128280A0 (en) 1996-08-01 1997-07-28 Method fro treating bipolar disorder

Country Status (19)

Country Link
EP (1) EP0821955B1 (no)
JP (1) JP2000515547A (no)
KR (1) KR20000029647A (no)
CN (1) CN1226165A (no)
AT (1) ATE213413T1 (no)
AU (1) AU716972B2 (no)
BR (1) BR9710901A (no)
CA (1) CA2261802C (no)
CZ (1) CZ27299A3 (no)
DE (1) DE69710526T2 (no)
DK (1) DK0821955T3 (no)
EA (1) EA199900174A1 (no)
ES (1) ES2171838T3 (no)
HU (1) HUP9904578A2 (no)
IL (1) IL128280A0 (no)
NO (1) NO990436D0 (no)
PL (1) PL331407A1 (no)
PT (1) PT821955E (no)
WO (1) WO1998005324A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
MX2021003621A (es) 2018-09-28 2022-04-13 Karuna Therapeutics Inc Composiciones y metodos para tratar trastornos mejorados por medio de activacion de receptor muscarinico.
CN111430027B (zh) * 2020-03-18 2023-04-28 浙江大学 基于肠道微生物的双相情感障碍生物标志物及其筛选应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
CA2169839C (en) * 1993-08-19 2002-06-11 Franklin Porter Bymaster Antipsychotic method
US5929247A (en) * 1994-10-24 1999-07-27 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
ES2144581T3 (es) * 1994-10-31 2000-06-16 Lilly Co Eli Tetrahidropiridina oxadiazol o tiadiazol para tratar la ansiedad.

Also Published As

Publication number Publication date
AU716972B2 (en) 2000-03-09
WO1998005324A1 (en) 1998-02-12
EA199900174A1 (ru) 1999-08-26
ATE213413T1 (de) 2002-03-15
HUP9904578A2 (hu) 2000-06-28
NO990436L (no) 1999-01-29
DE69710526T2 (de) 2002-10-02
EP0821955A3 (en) 1998-04-22
ES2171838T3 (es) 2002-09-16
CZ27299A3 (cs) 1999-08-11
NO990436D0 (no) 1999-01-29
EP0821955B1 (en) 2002-02-20
CA2261802A1 (en) 1998-02-12
PL331407A1 (en) 1999-07-19
AU4046897A (en) 1998-02-25
EP0821955A2 (en) 1998-02-04
CA2261802C (en) 2006-11-07
BR9710901A (pt) 1999-08-17
PT821955E (pt) 2002-07-31
CN1226165A (zh) 1999-08-18
JP2000515547A (ja) 2000-11-21
DK0821955T3 (da) 2002-03-18
KR20000029647A (ko) 2000-05-25
DE69710526D1 (de) 2002-03-28

Similar Documents

Publication Publication Date Title
SG47520A1 (en) New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
TW269678B (no)
MX9302932A (es) Nuevas 4-aza-5&-androstan-3-onas 7b-substituidas como inhibidores de la5&-reductasa.
HU9301361D0 (en) Method for producing 4-aryl-piperazines and 4-aryl-piperidines
IL119118A0 (en) 9-Ú(Haloacyl) amido¾-7- (substituted)-6- demethyl-6-deoxytetracycline intermediates
GB9722520D0 (en) Compounds
CY2543B1 (en) 9-Ä(Substituted glycyl)amidoÜ-6-(substituted)-5-hydroxy-6-deoxytetracyclines
GB9406857D0 (en) Improvements in or relating to organic compounds
HU9403311D0 (en) NEW 7BéTA-SUBSTITUTED-4-AZA-5ALPHA-CHOLESTAN-ONES AS 5-ALPHA-REDUCTASE INHIBITORS
DE69814635D1 (de) Verfahren zur herstellung von 2-hydroxybenzamidderivaten
EP0924199A4 (no)
TW287103B (no)
IL147575A0 (en) Method for purifying keratinocyte growth factors
IL128280A0 (en) Method fro treating bipolar disorder
IL128028A0 (en) Treatment of psychotic disorders
MY133014A (en) Method for treating copd
ZA958609B (en) Method for purifying keratinocyte growth factors
ES2065745T3 (es) Sintesis de compuestos de 1alfa-hidroxi-secosterol.
TW277059B (no)
ZA983298B (en) Methods for reducing fibrinogen.
DE69711506D1 (de) Methylsulfomycin 1, Verfahren zu dessen Herstellung und Verwendung
EP0412941A3 (en) Phospholipids for the treatment of multiple sclerosis
GR3036968T3 (en) Adamantyl substituted oxindoles as pharmaceutical agents
FR2708203B1 (fr) Procédé d'inhibition de la perception des odeurs.